Why Healthy Volunteer Retention Impacts Data Quality More Than You Think
Healthy volunteers are the backbone of many early phase clinical trials. Phase I studies, including first-in-human, bioequivalence (BE), and pharmacokinetic (PK) studies, rely on consistent participation from healthy individuals to generate reliable safety and pharmacokinetic data. While recruitment often receives the most attention during study planning, retention is just as critical to the integrity and […]
Designing First-in-Human Studies for Speed Without Sacrificing Safety
The transition from preclinical research to human testing represents one of the most critical milestones in drug development. First-in-human (FIH) studies are where theoretical promise meets clinical reality. For sponsors, these early Phase I trials must accomplish two goals simultaneously: generate high-quality safety and pharmacokinetic data while maintaining development momentum. Speed matters in today’s competitive […]
What Regulators Expect From Electronic Source Data in 2026
Electronic source, or eSource, is no longer an emerging capability in clinical research. By 2026, regulators increasingly assume that some portion of trial data will originate electronically, whether through EHR-to-EDC integration, ePRO, wearable devices, eConsent, centralized imaging platforms, or direct data entry into an eCRF. The regulatory focus has shifted from whether electronic systems are […]
The Hidden Operational Risks of Multi-Cohort Dose Escalation Studies
Multi-cohort dose escalation studies are central to early phase drug development. They generate the safety, tolerability, and pharmacokinetic (PK) insights needed to support dose progression and inform later-stage planning. While the scientific framework of these studies is well understood, their operational complexity is often underestimated. Behind every dose escalation decision sits a tightly coordinated sequence […]
Managing Protocol Amendments Without Disrupting Early Phase Timelines
Protocol amendments are an unavoidable reality in early phase clinical development. As first-in-human and early pharmacology studies progress, new safety findings, emerging pharmacokinetic data, regulatory feedback, and operational learnings often require adjustments. While amendments can strengthen study quality and protect participants, they also introduce a risk that sponsors know well: delays, budget increases, and disruption […]
What You Need to Know About Audit Prep
Introduction Audit readiness is no longer a reactive exercise reserved for the final stages of a clinical program. For early-phase trials, regulatory inspections and sponsor audits can occur at any point in the study lifecycle. As data integrity requirements continue to tighten and digital systems become more complex, audit preparation must be embedded into daily […]
How Stratification Is Changing Trial Populations in Phase I
Introduction Phase I clinical trials have traditionally focused on enrolling healthy volunteers under tightly controlled inclusion and exclusion criteria. While this model has supported early safety and pharmacokinetic evaluation, it is increasingly insufficient for today’s targeted, biomarker-driven therapies. As drug development shifts toward precision medicine, stratification is becoming a core design element even at the […]
Biologics vs. Biosimilars: What Makes Their Clinical Evaluation Different?
Introduction Biologic medicines now represent one of the fastest growing segments of the global pharmaceutical market. Monoclonal antibodies, recombinant proteins, cell based therapies, and other large molecule products are transforming how diseases such as cancer, autoimmune disorders, and rare genetic conditions are treated. As patents expire on many of these therapies, biosimilars are entering development […]